JP2014525270A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525270A5
JP2014525270A5 JP2014528597A JP2014528597A JP2014525270A5 JP 2014525270 A5 JP2014525270 A5 JP 2014525270A5 JP 2014528597 A JP2014528597 A JP 2014528597A JP 2014528597 A JP2014528597 A JP 2014528597A JP 2014525270 A5 JP2014525270 A5 JP 2014525270A5
Authority
JP
Japan
Prior art keywords
erbb2 gene
patient
cancer
hypomethylation
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528597A
Other languages
English (en)
Japanese (ja)
Other versions
JP6297490B2 (ja
JP2014525270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/053114 external-priority patent/WO2013033380A1/en
Publication of JP2014525270A publication Critical patent/JP2014525270A/ja
Publication of JP2014525270A5 publication Critical patent/JP2014525270A5/ja
Application granted granted Critical
Publication of JP6297490B2 publication Critical patent/JP6297490B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528597A 2011-08-31 2012-08-30 診断マーカー Expired - Fee Related JP6297490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529917P 2011-08-31 2011-08-31
US61/529,917 2011-08-31
PCT/US2012/053114 WO2013033380A1 (en) 2011-08-31 2012-08-30 Diagnostic markers

Publications (3)

Publication Number Publication Date
JP2014525270A JP2014525270A (ja) 2014-09-29
JP2014525270A5 true JP2014525270A5 (enExample) 2015-03-05
JP6297490B2 JP6297490B2 (ja) 2018-03-20

Family

ID=46826936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528597A Expired - Fee Related JP6297490B2 (ja) 2011-08-31 2012-08-30 診断マーカー

Country Status (13)

Country Link
US (4) US20130084286A1 (enExample)
EP (1) EP2751285B2 (enExample)
JP (1) JP6297490B2 (enExample)
KR (1) KR20140057356A (enExample)
CN (1) CN104024432B (enExample)
AU (1) AU2012301889B2 (enExample)
BR (1) BR112014004762A2 (enExample)
CA (1) CA2845179A1 (enExample)
IL (1) IL230851A0 (enExample)
MX (1) MX2014002436A (enExample)
RU (1) RU2614254C2 (enExample)
SG (1) SG2014011316A (enExample)
WO (1) WO2013033380A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9984201B2 (en) 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
EP3470528B1 (en) * 2016-06-10 2024-09-25 Hirofumi Mukai Method for predicting effect of pharmacotherapy on cancer
WO2018009707A1 (en) 2016-07-06 2018-01-11 Youhealth Biotech, Limited Solid tumor methylation markers and uses thereof
US10513739B2 (en) 2017-03-02 2019-12-24 Youhealth Oncotech, Limited Methylation markers for diagnosing hepatocellular carcinoma and lung cancer
CN110511997A (zh) 2018-05-22 2019-11-29 广州市康立明生物科技有限责任公司 肿瘤标志物、甲基化试剂、试剂盒及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
EP0672035A1 (en) 1993-10-01 1995-09-20 Novartis AG Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP0682027B1 (de) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
AU711592B2 (en) 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
ATE212993T1 (de) 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
DK9500262U4 (da) 1995-07-07 1996-10-07 Bonus Energy As Bundramme til vindmøllehus samt vindmølle omfattende samme
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6140317A (en) 1996-01-23 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU716383B2 (en) 1996-03-15 2000-02-24 Novartis Ag Novel N-7-heterocyclyl pyrrolo(2,3-d)pyrimidines and the use thereof
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
DE69738468T2 (de) 1996-08-23 2009-01-08 Novartis Ag Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6699666B1 (en) * 1998-09-18 2004-03-02 Kyowa Hakko Kogyo Co., Ltd. Method for the diagnosis of cell proliferative disease
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
HK1047236A1 (zh) 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
WO2003049740A1 (en) 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20040132097A1 (en) 2002-06-19 2004-07-08 Bacus Sarah S. Method for predicting response to epidermal growth factor receptor-directed therapy
EP2339025B1 (en) 2002-06-26 2013-10-09 Cold Spring Harbor Laboratory Methods for determining the methylation profiles
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2004063709A2 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
AU2004211955B2 (en) 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
JP4453297B2 (ja) 2003-05-27 2010-04-21 トヨタ自動車株式会社 車両用遊星歯車式多段変速機
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
WO2005090607A1 (en) * 2004-03-08 2005-09-29 Rubicon Genomics, Inc. Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200706804B (en) * 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US7851154B2 (en) * 2005-07-22 2010-12-14 Simon Daniel Spivack GC tag-modified bisulfite genomic DNA sequencing for continuous methylation spectra
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
WO2009042618A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
US8841268B2 (en) * 2008-05-07 2014-09-23 Sapporo Medical University Method and kit for detection of cancer, and therapeutic agent for cancer
US8193321B2 (en) 2008-09-03 2012-06-05 Genentech, Inc. Multispecific antibodies
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2011051414A1 (en) * 2009-10-28 2011-05-05 Signature Diagnostics Ag Method for the prognosis of ovarian carcinoma

Similar Documents

Publication Publication Date Title
JP2014531213A5 (enExample)
Subbiah et al. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
Zhou et al. MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1
Lee et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells
JP6980762B2 (ja) 抗腫瘍薬の調製におけるｖｃｐ阻害剤及び腫瘍溶解性ウイルスの使用
RU2014110228A (ru) Диагностические маркеры
Gomez et al. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
NZ629273A (en) Compositions and methods for the treatment of infections and tumors
Young et al. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
RU2017125053A (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
WO2007143752A3 (en) Targets in breast cancer for prognosis or therapy
JP2014525270A5 (enExample)
JP2015504847A5 (enExample)
Vecchio et al. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies?
Deng et al. Long non-coding RNA HOTTIP promotes tumor growth and inhibits cell apoptosis in lung cancer
WO2012061683A3 (en) Methods for treating cancer
Wang et al. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells
Bai et al. Serine/threonine kinase CHEK1-dependent transcriptional regulation of RAD54L promotes proliferation and radio resistance in glioblastoma
RU2014110895A (ru) Диагностические маркеры
Kutkowska et al. Non-small cell lung cancer-mutations, targeted and combination therapy
WO2016123679A1 (en) A method of treatment
Tan et al. P3. 02b-117 Phase Ib Results from a Study of Capmatinib (INC280)+ EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Topic: EGFR RES
JP2016504046A5 (enExample)
CN109453385B (zh) 一种用于治疗癌症的组合物及其应用
RU2014110271A (ru) Восприимчивость к ингибиторам ангиогенеза